The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Abstract
Purpose: This phase II study investigated the efficacy and tolerability of motesanib, an investigational, highly selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit in advanced medullary thyroid cancer (MTC). Patients and Methods: Patients with locally advanced or metastatic, progressive or symptomatic MTC received motesanib 125 mg/d orally for up to 48 weeks or until unacceptable toxicity or disease progression. The primary end point was objective response by independent review. Other end points included duration of response, progression-free survival, safety, pharmacokinetics, and changes in tumor markers. Results: Of 91 enrolled patients who received motesanib, two (2%) achieved objective response (95% CI, 0.3% to 7.7%); their duration of response was 32 weeks (censored) and 21 weeks (disease progressed). Eighty-one percent of patients had stable disease (48% had durable stable disease ≥ 24 weeks), 8% had disease progression as best response, and 9% were not evaluated; 76% experienced a decrease from baseline in target lesion measurement. Median progression-free survival was 48 weeks (95% CI, 43 to 56 weeks). Among patients with tumor marker analysis, 69 (83%) of 83 and 63 (75%) of 84 had decreased serum calcitonin and carcinoembryonic antigen during treatment, respectively, compared with baseline. The most common treatment-related adverse events were diarrhea (41%), fatigue (41%), hypothyroidism (29%), hypertension (27%), and anorexia (27%). In pharmacokinetic analyses, motesanib trough concentrations were lower compared with differentiated thyroid cancer patients from the same study. Conclusion: Although the objective response rate was low, a significant proportion of MTC patients (81%) achieved stable disease while receiving motesanib.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The need for a substantially increased dose of LT4 has been reported in athyreotic patients prescribed tyrosine kinase inhibitors such as imatinib (188), motesanib (189), sorafenib (190), sunitinib, and vandetanib (191).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [189]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Collett, D. (1991) · Chapman & Hall/CRC eBooks · doi:10.1007/978-1-4899-4475-7 · Cited by 1,960
Sherma, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12488-9 · Cited by 926
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E. J., Kim, S., Bycott, P. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 622
Carlson, K. M., Dou, S., Chi, D., Scavarda, N. J., Toshima, K., Jackson, C. E., Wells, S. A., Goodfellow, P. J., & Donis-Keller, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1579 · Cited by 599
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531
Self-citationMotesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470
Self-citationHypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 402
Bunone, G., Vigneri, P. G., Mariani, L., Butó, S., Collini, P., Pilotti, S., Pierotti, M. A., & Bongarzone, I. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65515-0 · Cited by 395
AACE/AAES MEDICAL/SURGICAL Guidelines for Clinical Practice: Management of Thyroid Carcinoma
Cobin, R. H., Gharib, H., Bergman, D. A., Clark, O. H., Cooper, D. S., Daniels, G. H., Dickey, R. A., Duick, D. S., Garber, J. R., HAY, I. D., et al. (2001) · Endocrine Practice · doi:10.4158/ep.7.3.202 · Cited by 366
Flagged first, then by citations
Research works printed but not linked: 3
- Coxon A, 2007, Proc Am Assoc Cancer Res, 48, 71
- Baudin E, 2007, Horm Res, 68, 28
- Tsai MS, 1994, J Clin Endocrinol Metab, 78, 1261
Cited by
Sorted by citations
Items 301–342 of 342
INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA
Saraiva, S., Morgado, S., & Morgado, M. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.25756/rpf.v5i3.44
New advances in the diagnosis, medical management and follow-up of medullary thyroid cancer
Dökmetaş, H. S., Kılıçlı, F., Özben, V., & Tapan, Ü. (2011) · DergiPark (Istanbul University) · doi:10.7197/cmj.v33i4.1008001190
Surgery for Medullary Thyroid Cancer
Rowland, K. J., & Moley, J. F. (2012) · Springer eBooks · doi:10.1007/978-3-642-23459-0_18
Sorafenib in thyroid cancer—a retrospective case series
Gamerith, G., Pircher, A., Amann, A., Cima, K., Gasser, K., Lenzhofer, M., Lind, P., Bareck, E., Wöll, E., & Hilbe, W. (2012) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-012-0033-0
Targeted Therapies in Thyroid Cancer
Abadin, S. S., Busaidy, N. L., & Perrier, N. D. (2015) · Head and neck cancer clinics · doi:10.1007/978-81-322-2434-1_11
Les inhibiteurs des tyrosine kinases dans les cancers thyroïdiens
Illouz, F. (2010) · La Lettre du cancérologue
Promising data, but challenges remain in selecting appropriate TKIs
Mirshahidi, H. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70050-5
Schott, M. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79439-7
Lorch, J. H., & Voigt, W. (2012) · US Endocrinology · doi:10.17925/use.2012.08.02.122
McFarland, D. C., Varier, I. V., & Misiukiewicz, K. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-20523-6_17
Giani, C., Matrone, A., & Elisei, R. (2015) · Springer eBooks · doi:10.1007/978-3-319-22401-5_41
Self-citationRadioiodine-Refractory Thyroid Cancer: Restoring Response to Radioiodine Therapy
Fish, S. A., & Fagin, J. A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3314-3_68
Griebeler, M. L., Gharib, H., & Thompson, G. B. (2013)
Radionuclide Therapy of Thyroid Tumors
Elisei, R., Agate, L., Mazzarri, S., Bottici, V., Guidoccio, F., Molinaro, E., Boni, G., Ferdeghini, M., & Mariani, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_49-1
Self-citationEfstathiadou, Z. A., Tsentidis, C., Bargiota, Α., Daraki, V. N., Kotsa, K., Ntali, G., Papanastasiou, L., Tigas, S., Toulis, K. A., Pazaitou‐Panayiotou, K., et al. (2019) · Endocrine Abstracts · doi:10.1530/endoabs.63.gp86
Les cancers réfractaires de la thyroïde : progrès dans leur prise en charge
Schlumberger, M. J. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30825-8
Self-citationNovel targeted therapies for the treatment of advanced thyroid cancer: a review
Britt, C. J., & Thorpe, E. J. (2020) · Annals of Thyroid · doi:10.21037/aot.2020.03.01
Acute pancreatitis induced by drugs used in the treatment of solid malignant neoplasms
Atabiekov, I., Golovin, A. V., FESAK, I. V., Kazimov, K. N., & Dzhansyz, I. N. (2021) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20211001146
Targeted therapies for thyroid cancer.
Viola, D., & Elisei, R. (2013) · CINECA IRIS Institutial research information system (University of Pisa)
Self-citationShong, Y. K. (2021) · International Journal of Thyroidology · doi:10.11106/ijt.2021.14.2.98
Elisei, R., & Jarząb, B. (2018) · Endocrinology · doi:10.1007/978-3-319-29195-6_22-1
Self-citationUncommon Cancers of the Thyroid
Konda, B., & Shah, M. H. (2017) · doi:10.1002/9781119196235.ch48
Current awareness: Pharmacoepidemiology and drug safety
(2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1847
Multiple Endocrine Neoplasia Type 2
Hu, M. I.-N., & Gagel, R. F. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00151-9
Locati, L. D., Greco, A., Borrello, M. G., Carcangiu, M. L., Bossi, P., Granata, R., & Licitra, L. F. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_3
Self-citationEndokrinologische Erkrankungen
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50013-3
Giani, C., Matrone, A., & Elisei, R. (2020) · Springer eBooks · doi:10.1007/978-3-030-61919-0_37
Self-citationDagan, R., & Amdur, R. J. (2017) · doi:10.1002/9781119341154.ch17
(2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.217
Chatal, J. F., Barbet, J., Kraeber‐Bodéré, F., & Goldenberg, D. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4021-5_9
Feldkamp, J., Schulte, K., Schmid, K. W., Heverhagen, J. T., Höffken, H., Pfestroff, A., Rüschoff, J., Hofmann, M., Derwahl, K.-M., Zielke, A., et al. (2012) · Springer eBooks · doi:10.1007/978-3-642-14285-7_2
(2016) · Elsevier eBooks · doi:10.1016/b978-0-323-39255-6.50314-8
Radionuclide Therapy of Thyroid Tumors
Elisei, R., Agate, L., Mazzarri, S., Bottici, V., Guidoccio, F., Molinaro, E., Boni, G., Ferdeghini, M., & Mariani, G. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_49-2
Self-citationLi, G., Chen, Y., Wei, K., Deng, H., & Chen, Y. (2022) · doi:10.22541/au.166971966.65533901/v1
Radionuclide Therapy of Thyroid Tumors
Elisei, R., Agate, L., Mazzarri, S., Bottici, V., Guidoccio, F., Molinaro, E., Boni, G., Ferdeghini, M., & Mariani, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_49
Self-citationMolecular Target Therapy for Pathologists in Advanced Thyroid Carcinoma
Song, Y. S., & Park, Y. J. (2023) · Springer eBooks · doi:10.1007/978-981-99-6782-7_82
Laçin, Ş., & Yalçın, Ş. (2024) · Springer eBooks · doi:10.1007/978-3-031-56968-5_23
Cancers de la thyroïde, nouvelles perspectives et prise en charge
Lamartina, L., & Schlumberger, M. J. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)44592-7
Self-citationBindingDB (2019) · UC San Diego · doi:10.7270/q23x88sh
BindingDB (2012) · UC San Diego · doi:10.7270/q2bv7h06
Metadata
- Authors
- Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., Eschenberg, M. J., Sun, Y.-N., Juan, T., Stepan, D. E., & Sherman, S. I.
- Affiliations
- University of Siena (IT)
- From the Institut Gustave Roussy, University Paris Sud, Villejuif; Centre Léon Bérard, Lyon, France; University of Pisa, Pisa; Istituto Nazionale dei Tumori, Milan; University of Siena, Siena, Italy; Odense University Hospital, Odense, Denmark; Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Université Catholique de Louvain, Brussels, Belgium; Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Amgen, Thousand...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-10
- Volume
- 27
- Issue
- 23
- Pages
- 3794-3801
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112475888
- Cited by
- 340
- References
- 35
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 14 · 2019: 12 · 2018: 11 · 2017: 14 · 2016: 22 · 2015: 26 · 2014: 38 · 2013: 36 · 2012: 46
- FWCI
- 33.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- motesanib, medullary thyroid carcinoma, metastatic thyroid cancer, VEGFR inhibitors, platelet-derived growth factor receptor, KIT inhibitors, tyrosine kinase inhibitors, progression-free survival, stable disease, calcitonin, carcinoembryonic antigen, pharmacokinetics, adverse events, diarrhea, hypothyroidism
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Female, Humans, Indoles, Male, Middle Aged, Niacinamide, Oligonucleotides, Thyroid Neoplasms, Treatment Outcome, Receptors, Platelet-Derived Growth Factor, Carcinoma, Medullary, Proto-Oncogene Proteins c-kit, Receptors, Vascular Endothelial Growth Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
